Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report its next earnings on Feb 9 – Feb 13 (Est.). The company reported the earnings of $-1.21/Share in the last quarter where the estimated EPS by analysts was $-1.14/share. The difference between the expected and actual EPS was $-0.07/share, which represents an Earnings surprise of -6.1%.
Many analysts are providing their Estimated Earnings analysis for Alnylam Pharmaceuticals, Inc. and for the current quarter 12 analysts have projected that the stock could give an Average Earnings estimate of $-1.32/share. These analysts have also projected a Low Estimate of $-1.52/share and a High Estimate of $-1.17/share.
In case of Revenue Estimates, 12 analysts have provided their consensus Average Revenue Estimates for Alnylam Pharmaceuticals, Inc. as 10.95 Million. According to these analysts, the Low Revenue Estimate for Alnylam Pharmaceuticals, Inc. is 1.5 Million and the High Revenue Estimate is 15.5 Million. The company had Year Ago Sales of 7.55 Million.
Some buy side analysts are also providing their Analysis on Alnylam Pharmaceuticals, Inc., where 2 analysts have rated the stock as Strong buy, 6 analysts have given a Buy signal, 7 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. 15 Analysts reported that the Price Target for Alnylam Pharmaceuticals, Inc. might touch $106 high while the Average Price Target and Low price Target is $62.93 and $36 respectively.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. Alnylam Pharmaceuticals, Inc. got Downgrade on 7-Oct-16 where investment firm Morgan Stanley Downgrade the stock from Overweight to Equal-Weight.
Alnylam Pharmaceuticals, Inc. closed its last trading session at $46.03 with the loss of -4.69%. The Market Capitalization of the company stands at 3.76 Billion. The Company has 52-week high of $109.1 and 52-week low of $31.38. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.59% where SMA50 and SMA200 are -8.63% and -27.76% respectively. The Company Touched its 52-Week High on Dec 4, 2015 and 52-Week Low on Nov 3, 2016.
The Relative Volume of the company is 3.52 and Average Volume (3 months) is 1.47 million. Alnylam Pharmaceuticals, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -28.7%. The Return on Equity (ROE) value stands at -34%. While it’s Return on Investment (ROI) value is -23.4%.
While looking at the Stock’s Performance, Alnylam Pharmaceuticals, Inc. currently shows a Weekly Performance of -3.9%, where Monthly Performance is 23.23%, Quarterly performance is -37.19%, 6 Months performance is -40.81% and yearly performance percentage is -58.61%. Year to Date performance value (YTD perf) value is -53.4%. The Stock currently has a Weekly Volatility of 6.34% and Monthly Volatility of 7.23%.